Adjuvant Effects of Platycodin D on Immune Responses to Infectious Bronchitis Vaccine in Chickens

Yefei Zhou, Meixian Zhou and Shanguo Mao

Department of Life Science, Nanjing Xiaozhuang University, Nanjing 211171, China

Running title: Platycodin D Acts as an Adjuvant

Correspondence: Dr. Yefei Zhou, Department of Life Science, Nanjing Xiaozhuang University, Nanjing 211171, China. (E-mail: yfzhou@njxzc.edu.cn)
Abstract

Adjuvants are common vaccine components. Novel adjuvants may improve the protective immunity conferred by vaccines against poultry diseases. Here, a less-hemolytic saponin, platycodin D (PD), isolated from the root of *Platycodon grandiflorum* was investigated as a potential alternative adjuvant. PD was tested as an adjuvant in the infectious bronchitis (IB) vaccine, because the existing IB vaccine has often failed to induce effective immune responses. The adjuvant activity of PD in conjunction with IB vaccine was evaluated in this study. Compared to control treatment, PD treatment significantly increased the proliferation of chicken peripheral blood mononuclear cells, concentration of interferon-γ in culture supernatants, and anti-IB antibody titer. In chickens pre-challenged with the Mass 41 infectious bronchitis virus (IBV), PD administration resulted in fewer and less severe clinical signs, lower mortality rate, and higher protection compared to control treatment. Histopathological examination showed that the lungs and kidneys of PD-treated chickens displayed fewer pathological lesions than those of control chickens. Our results also demonstrated that this new vaccine adjuvant improved chicken humoral and cellular immune responses without any side effects. Hence, our findings suggest that PD might serve as an effective adjuvant in IBV vaccines.

**Key words:** adjuvant, immunogenicity, infectious bronchitis, platycodin D, *Platycodon grandiflorum*
Introduction

Infectious bronchitis (IB), caused by the infectious bronchitis virus (IBV), is an acute and highly contagious disease of chickens; IBV leads to severe economic losses in the poultry industry (Amarasinghe et al., 2017, Bermudez & Stewart-Brown, 2003). Since IB pathogenesis is characterized by respiratory symptoms that often lead to complex infections and secondary bacterial disease, IB is an important concern for the poultry industry (De Wit et al., 2017, Abd El Rahman et al., 2010). Though both live-attenuated and inactivated vaccines are widely used to control IBV, outbreaks occasionally occur in endemic areas (Dhama et al., 2014, Mase et al., 2010). Several strategies, including use of powerful adjuvants to enhance immunogenicity, optimizing delivery methods, selecting appropriate immunization routes, and targeting effective antigen presentation have been employed to improve the efficacy of the IBV vaccine (Zeshan et al., 2011, Chen et al., 2010, Wang et al., 2009).

Adjuvants elicit immune responses through different signaling pathways, and can improve vaccine formulations for better protection (Antúnez et al., 2016, Czajka et al., 2012, Aghasadeghi et al., 2011). However, as alum or oil adjuvants may cause local post-vaccination reactions in animals, these widely used chemical adjuvants are often associated with several disadvantages (Martinez-Lopez et al., 2014, Liu et al., 2013). Therefore, it is crucial to develop novel adjuvants for poultry vaccines.

Traditional Chinese medicine (TCM) uses natural products that have been employed by humans for centuries. TCMs contain numerous bioactive ingredients with
beneficial effects, and have thus attracted much attention (Han et al., 2011). Saponins, which are commonly found in plants, are a highly heterogeneous group of glycosides that have been known to exhibit adjuvant properties since the 1920s (Sjölander and Cox, 1998). The addition of saponins to drinking water was shown to increase vaccination efficacy against Newcastle disease, avian influenza, and infectious bursal disease in chickens (Yu et al., 2015; Chi et al., 2017).

The root of *Platycodon grandiflorum* A. DC (Campanulaceae) is a well-known TCM that has been employed as an expectorant for pulmonary diseases and as a remedy for respiratory disorders (Nyakudya et al., 2014). Platycodin D (PD) is a less hemolytic and more stable saponin isolated from the root of *P. grandiflorum* (Choi et al., 2018). Although PD has been previously shown to act as a potent adjuvant by enhancing specific immune responses to ovalbumin (Xie et al., 2008) and a recombinant hepatitis B surface antigen (Xie et al., 2009), it is unclear whether PD is an effective adjuvant for poultry vaccines.

The adjuvant performance of PD with the inactivated IB vaccine was investigated in the present study. We aimed to test the efficacy and safety of PD, and to determine its optimum dosage. Our results may provide a theoretical basis for the development of novel adjuvants for poultry vaccines.
Materials and Methods

Animals

All experimental protocols were approved by the Institutional Animal Care and Ethics Committee of Nanjing Xiaozhuang College (permit number IACECNAU20140221), and were performed in accordance with the International Guiding Principles for Biomedical Research Involving Animals.

Virus and adjuvant

Two IBV strains, H120 and Mass 41 (M41), obtained from Jiangsu Provincial Academy of Agricultural Science, were propagated in the allantoic cavities of 10-day-old specific-pathogen-free (SPF) embryonated chicken eggs, and the allantoic fluid from each egg was harvested 36 h post inoculation. The 50% embryo infection dose (EID$_{50}$) was calculated by inoculating serial 10-fold dilutions of each virus strain into 10-day-old SPF embryonated chicken eggs following the protocol of Reed and Muench (Reed & Muench, 1938). PD (C$_5$H$_9$O$_2$; molecular weight: 1224.5854) was purchased from Sigma-Aldrich (St. Louis, Missouri, USA; purity: HPLC ≥ 98%; product number: SMB00424).

Preparation of vaccines

Allantoic fluid aliquots from 10-day-old embryos inoculated with the IBV H120 vaccine strain (minimum titer: $10^6$ EID$_{50}$/mL) were harvested and used without modification. The live purified virus was inactivated by incubation in 0.4% formaldehyde...
for 2 h with constant stirring at 20°C and was stored for 24 h at 37°C. PD and the inactivated IBV H120 antigen were combined at a ratio of 3:1 (vol:vol). Three sets of inocula were prepared, with final PD concentrations of 0.25, 0.5, and 1 mg/mL. Three additional sets of inocula were also prepared: inactivated IBV H120 antigen alone (vaccine group), Al(OH)₃ (0.5 mg/mL) plus H120 antigen (positive control), and phosphate buffered saline (PBS; negative control).

**Chicken immunization**

We randomly divided 180 SPF chickens (age: 7 d; average body weight: 95 g) into six treatment groups; each treatment included three replicate cages (ten birds per cage). Chickens in each treatment group were individually inoculated via intramuscular injection with 100× the mean embryo infectious dose of one of the vaccine preparations in 0.2 mL. The initial vaccination was boosted with an equivalent dose of the same vaccine preparation at day 14 post initial inoculation.

**Isolation and culture of chicken peripheral blood mononuclear cells (PBMCs) for proliferation assay**

Peripheral blood samples were obtained from chicken wing veins at 0, 14, and 28 days post immunization (dpi), and transferred immediately into aseptic capped tubes containing sodium heparin. Each sample was diluted with an equal volume of Hank’s solution, and carefully layered over a lymphocyte separation medium (Ficoll-Hypaque;
ρ: 1.077 ± 0.002; Rong Sheng Biostix Inc, Nanjing, Jiangsu, China). After centrifugation for 20 min at 400 × g, the white cloud-like lymphocyte band was collected and washed twice with RPMI 1640 medium (Gibco, Waltham, Massachusetts, USA) without fetal bovine serum. The resulting mononuclear cell preparations were washed twice with RPMI 1640 medium, followed by centrifugation at 400 × g. Cell viability was determined using trypan blue vital staining. The resulting pellet was resuspended in RPMI 1640 medium containing benzyl penicillin (100 U/mL), streptomycin (100 mg/mL), and 10% fetal bovine serum to a achieve a final concentration of 5 × 10^6 cells/mL. Cells were seeded on 12-well plates (Nunclon™ Delta) at a concentration of 10^5 cells/well. After a 12 h incubation at 37°C, the PBMCs were restimulated with various substances, including inactivated IBV H120 antigen (10^2 HA units/mL) (vaccine group), inactivated IBV H120 antigen (10^2 HA units/mL) plus 0.5 μg PD at one of three different doses (PD group), 0.5 μg Al(OH)₃ [Al(OH)₃ group]; or 100 μL PBS (PBS group). Cell proliferation was quantified based on restimulated PBMCs and assessed through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The entire analysis was performed in triplicate.

After a 44 h incubation at 37°C in a humidified atmosphere with 5% CO₂ (Revco), 20 μL filter-sterilized thiazolyl blue tetrazolium bromide (5 mg/mL in calcium- and magnesium-free PBS) was added to each well, and the plates were reincubated for 4 h. The plates were centrifuged for 10 min at 1000 × g at room temperature, and the supernatant was carefully discarded. Then, 10 μL dimethyl sulfoxide was added to each
well, and the plates were shaken for 5 min to dissolve the formazan crystals. The optical density at 570 nm (OD$_{570}$) of the cells in each well was measured using a microtiter enzyme-linked immunosorbent assay (ELISA) reader (Model DG-3022; East China Vacuum Tube Manufacturer), and the stimulation index (SI) was calculated as the ratio of the OD$_{570}$ values of the stimulated cells to those of the negative control, as described previously (Jiang et al., 2006; Zhou et al., 2010).

Cytokine assay

Approximately $1 \times 10^6$ PBMCs were stimulated with the corresponding reagent for 24 h as described above, and the culture supernatants were collected for the measurement of interferon (IFN)-γ concentration. Supernatant cytokine concentration was determined using a sandwich ELISA kit (IFN-γ Chicken Antibody Pair; Cat. No. CAC1233; Invitrogen, Waltham, Massachusetts, USA), following the manufacturer’s instructions. Briefly, the coating antibody was prepared (Anti-Chicken IFN-γ; 0.25 mg/0.5 mL) and added to the plate. Then, 100 μL of the diluted cytokine standard, 100 μL of the sample, and 50 μL of the working detection antibody (Anti-Chicken IFN-γ Biotin; 0.031 mg/0.2 mL) was added to each well. Plates were incubated for 2 h at 37°C. After washing five times, 100 μL of the working streptavidin-HRP (Horseradish Peroxidase) solution was added to each well, and plates were incubated for 30 min at 37°C. The plates were washed five times, and 100 μL of Tetramethylbenzidine (TMB) was added to each well. After incubation in the dark for 20 min, 100 μL of stop solution (2 mol/L H$_2$SO$_4$)
was added to each well, and the absorbance was measured at 450 nm using an automatic ELISA reader (Bio-Tek, Winooski, VT, USA). Standard curves were drawn, and the concentration of cytokines in each well was calculated with respect to the standards. Each serum sample was tested in duplicate.

Serum hemagglutinin inhibition (HI) antibody assay in chickens

We randomly selected eight chickens from each group, and determined the serum HI antibody titer of each selected chicken. In brief, 0.5 mL of blood was drawn from the main brachial vein of each selected chicken into Eppendorf tubes at 0, 14, 21, and 28 dpi. The blood was allowed to clot at 37°C for 2 h. The serum was separated by centrifugation at 3860 × g for 15 min at 4°C and inactivated at 56°C for 30 min before use. The HI test was performed as stipulated by the Office of International des Epizooties (OIE, 2008) to determine the highest dilution of serum at which complete inhibition was still observed. The geometric mean titer was expressed as the reciprocal log2 value of the highest dilution that displayed HI (Habibi et al., 2017, Zeshan et al., 2011).

Challenge

The M41 strain of IBV was grown in 10-day-old embryonated chicken eggs until the allantoic fluid titer reached 5 × 10^6 EID_{50}/mL. After vaccination, as described above, 35-day-old chickens were challenged with 10^4 EID_{50} of M41 in 0.3 mL via the ocular-nasal route. Birds were monitored for 5 d post-challenge for any clinical signs or mortality.
Dead chickens were necropsied to confirm that death was due to IBV infection. All remaining live chickens were euthanized at 5 d post-challenge. The kidney and lung tissues were collected from all chickens, and their viral RNA levels were quantified using RT-PCR. Cumulative mortality over the 5 d challenge was calculated as the number of birds that survived the challenge divided by the total number of birds challenged (Khan et al., 2017, Meir et al., 2010).

*Pathological examination*

The collected kidney and lung tissues were fixed in 10% buffered neutral formalin, processed using standard histological procedures (Jain et al., 2015), and embedded in paraffin. The paraffin-embedded tissues were then cut into 5 μm-thick sections and stained using a standard hematoxylin and eosin (H&E) histological staining protocol.

*Statistical analysis*

Statistical analyses were performed by Student’s *t*-test and a one-way repeated measures analysis of variance (ANOVA) using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Data are shown as mean ± standard error (SE). The means of treatments were compared using Tukey’s multiple range tests. Differences were considered significant at *P* < 0.05.

*Results*
Effect of PD on chicken PBMC proliferation

PBMC proliferation at 28 dpi was significantly higher in chickens treated with 0.5 and 1 mg/mL PD compared to that in control group chickens ($P < 0.05$) (Figure 1). Chickens treated with 0.5 mg/mL PD showed the highest SI across all immunized groups.

Cytokine responses in chickens

The concentrations of IFN-γ at 14 and 28 dpi were significantly higher in chickens vaccinated with inactivated IBV H120 plus PD or Al(OH)₃ than those in control chickens mock vaccinated with PBS or H120 only (Figure 2). Of the three PD concentrations tested, chickens treated with 0.5 mg/mL PD showed the highest IFN-γ concentration.

Effects on serum antibody titer

No significant differences ($P > 0.05$) in HI antibody titer were identified among the PD treatment groups at 0 dpi, and no specific IBV antibodies were detected in the PBS group (Table 1). Antibody levels increased slowly in the group vaccinated with 0.25 mg/mL PD, but these levels were not significantly different from those of the control groups. The groups vaccinated with 0.25 and 1 mg/mL PD produced significantly more antibodies to IBV at 14 dpi, as compared to all other groups ($P < 0.05$). At 21 and 28 dpi, the antibody titers in the 0.5 and 1 mg/mL PD groups were significantly higher than those in the H120 group ($P < 0.05$).
Protection of chickens against IBV challenge

To evaluate the protective efficacy of the IBV vaccine with a PD adjuvant, all chickens were challenged with the IBV strain M41. Vaccination with IBV plus PD or Al(OH)₃ conferred greater protection than vaccination with IBV alone, as indicated by reduced morbidity, mortality, and clinical signs of IB in the chickens (Table 2). Chickens began to die or to show clinical signs of infection on day 4 after the challenge. The chickens injected with PBS alone were not protected against IBV infection, and developed cough, nasal discharge, and dyspnea. The death rate in the group injected with PBS was 43.3% at day 14 post-challenge, and the mortality rate in the 0.5 mg/mL group (0%) was significantly lower than that in all other groups ($P < 0.05$). Moreover, the clinical signs and pathological changes observed in the affected chickens in the H120 and PBS groups were more conspicuous and severe than those observed in the affected chickens in the immunized group.

To evaluate the level of protection after IBV challenge, the collected lung and kidney tissue samples were examined for IBV infection using RT-PCR. Results showed that the protective rates in the 0.5 and 1 mg/mL groups (96.7%) were significantly higher than those in the other three groups ($P < 0.05$).

On day 5 post-challenge, pathological lesions in the lungs and kidneys of chickens inoculated with PBS were characterized by epithelial degeneration, mild, moderate, or pronounced lymphoid accumulation in the epithelial tissue, focal necrosis, and increased
amounts of exudates. In the PD-immunized group, lesions were more moderate than those in the control groups (Figure 3). Thus, our results suggested that PD confers resistance against virulent IBV.

**Discussion**

Inoculation with commercially available inactivated IBV vaccines is not sufficient to prevent IBV infection due to the short duration of protection and limited cellular immune responses (Smith et al., 2015). It has been shown that adjuvants may enhance antigen-specific response and extend the duration of protection (Toro et al., 2012). PD is a potential less-hemolytic saponin adjuvant isolated from the root of *P. grandiflorum*. PD treatment was shown to significantly enhance specific antibody and cellular responses in mice, and simultaneously elicit a Th1 and Th2 immune response (Sun et al., 2011). Here, PD was used as an adjuvant. We evaluated how effectively PD induced immunity and protected chickens against IBV challenge. As expected, treatment with PD plus the inactivated IBV H120 antigen resulted in a higher IBV-specific antibody titer, greater T cell proliferation, and more robust protection against mortality. These results indicated that PD together with an IBV vaccine may confer preferably protection against IBV infection in chickens.

It is well known that cell-mediated immunity plays a crucial role in anti-infection and anti-tumor mechanisms, and can promote lymphocyte-mediated antibody production...
through lymphocytes sensitized to the corresponding antigen (Zhang et al., 2017). Vaccination induces cell-mediated responses by promoting lymphocyte proliferation and increasing cytokine production (Oliveira et al., 2016). The cytokine profile induced by an immune adjuvant plays an important role in the polarization of immune responses (Gan et al., 2019). Chicken IFN-γ activates macrophages, increases the expression levels of major histocompatibility complex I and II antigens in various cell types, and neutralizes viral replication (Andersen et al., 2017; Janardhana et al., 2007; Kano et al., 2009). Our proliferation assay indicated that PD treatment significantly increased lymphocyte proliferation in immunized chickens. In addition, PD treatment significantly increased IFN-γ concentration in the culture supernatants. These results indicated that PD treatment enhanced T and B lymphocyte activation, and induced humoral and cell-mediated immune responses in chickens. In addition, co-immunization with PD led to the secretion of the Th1 cytokine IFN-γ, suggesting that immunized chickens were able to elicit an adaptive immune response by synthesizing T cells and improving cell-mediated immunity.

Serological response is an important indicator of successful vaccination, as this response reflects the ability of the vaccine to attach, replicate, and induce immune responses, including humoral antibodies (Andoh et al., 2015). Humoral responses are an important element of protective immune responses against IBV (Chhabra et al., 2015), and it has been reported that high antibody levels are associated with protection against IBV infection (Okino et al., 2017). In this study, HI was used for the detection of IBV
humoral antibodies, as HI antibody levels are commonly used as indicators of protection
inactive vaccine (Katz & Kohn 1976). Indeed, HI antibody levels are typically used to
monitor the antibody response induced by an IBV vaccine (Awad et al., 2015). Therefore,
HI titer was an important factor for the assessment of vaccine adjuvant performance. Our
results indicated that the mean HI antibody titer production was dependent on the PD
concentration when injected intramuscular injection (i.m.) Co-administration of the
antigen and PD increased HI titers, and the titers of the PD groups were significantly
higher than those of the control or Al(OH)3 groups. This result strongly indicated that PD
improved antibody formation.

The results of the viral challenge indicated that chickens treated with PD were
better protected against IBV than unvaccinated chickens or chickens treated with the
inactive vaccine. The protection rate in the PD groups (0.5 and 1 mg/mL) was 96.7%,
indicating protective immunity against viral infection. Immune response analysis
indicated that viral challenge elicited a strong immune response and enhanced the
protection rate in the PD-treated groups. The immune response analysis and viral
challenge identified a strong immune response and remarkable protection rate in the
group inoculated with PD. These results suggest that use of PD as an adjuvant might
increase protection against IBV. The enhancement of immune responses with the PD
adjuvant was slightly higher than that with the Al(OH)3 adjuvant, thereby suggesting that
PD can be used as an adjuvant in IBV vaccines, and it might provide better protection
against IBV by stimulating both the humoral and cellular immune responses. Hence, these findings may have important implications in the design of IBV vaccine adjuvants.

Acknowledgements

This work was supported by a cooperation project in industry, education, and research of the Science and Technology Department of Jiangsu Province (No. BY2018026), and a cooperation project in industry, education and research of Nanjing Agricultural Committee (No. 2018RHJD10).

Conflicts of Interest

The authors declare no conflict of interest.
References

Abd El Rahman S., Winter C., El-Kenawy A., Neumann, U., Herrler, G. Differential sensitivity of well-differentiated avian respiratory epithelial cells to infection by different strains of infectious bronchitis virus. Journal of Virology, 84: 8949-8952. 2010.

Aghasadeghi MR., Salmani AS., Sadat SM., Javadi F., Memarnejadian A., Vahabpour R., Zabihollahi R., Moshiri A., Siadat SD. Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1. Current HIV Research, 9: 630-635. 2011.

Amarasinghe A., Abdul-Cader MS., Nazir S., De Silva Senapathi U., van der Meer F., Cork SC., Gomis S., Abdul-Careem MF. Infectious bronchitis corona virus establishes productive infection in avian macrophages interfering with selected antimicrobial functions. PLoS One, 12: e0181801. 2017.

Andoh K., Suenaga K., Sakaguchi M., Yamazaki K., Honda T. Decreased neutralizing antigenicity in IBV S1 protein expressed from mammalian cells. Virus Research, 208: 164-170. 2015.

Andersen SH., Vervelde L., Sutton K., Norup LR., Wattrang E., Juul-Madsen HR., Dalgaard TS. Quantification and phenotypic characterisation of peripheral IFN-γ producing leucocytes in chickens vaccinated against Newcastle disease. Veterinary Immunology and Immunopathology, 193-194: 18-28. 2017.
Antúnez LR., Livingston A., Berkland C., Dhar P. Physiochemical Properties of Aluminum Adjuvants Elicit Differing Reorganization of Phospholipid Domains in Model Membranes. Molecular Pharmaceutics, 13: 1731-1737. 2016.

Awad F., Forrester A., Baylis M., Lemiere S., Jones R., Ganapathy K. Immune responses and interactions following simultaneous application of live Newcastle disease, infectious bronchitis and avian metapneumovirus vaccines in specific-pathogen-free chicks. Research in veterinary science, 98:127-33. 2015.

Bermudez AJ., Stewart-Brown B. Disease prevention and diagnostic. In: Saif YM, editor. Disease of Poultry, 11th ed. Iowa: Iowa State University Press, pp 17-55. 2003.

Chen HY., Yang MF., Cui BA., Cui P., Sheng M., Chen G., Wang S.J., Geng JW. Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18. Vaccine, 28: 8112-8119. 2010.

Chhabra R., Forrester A., Lemiere S., Awad F., Chantrey J., Ganapathy K. Mucosal, Cellular, and Humoral Immune Responses Induced by Different Live Infectious Bronchitis Virus Vaccination Regimes and Protection Conferred against Infectious Bronchitis Virus Q1 Strain. Clinical and Vaccine Immunology, 22(9):1050-1059. 2015.

Choi Y., Kang S., Cha S.H., Kim H.S., Song K., Lee Y.J., Kim K., Kim Y.S., Cho S., Park Y. Platycodon saponins from Platycodi Radix (Platycodon grandiflorum) for
the Green Synthesis of Gold and Silver Nanoparticles. Nanoscale Research Letters, 13(1): 23. 2018.

Chi X., Bi S., Xu W., Zhang Y., Liang S., Hu S. Oral administration of tea saponins to relieve oxidative stress and immune suppression in chickens. Poultry Science, 96: 3058-3067. 2017.

Czajka H., Unal S., Ulusoy S., Usluer G., Strus A., Sennaroglu E., Guzik J., Topeli Iskit A., Dargiewicz A., Musial D., Caylan R., Dziduch J., Eskioglu E., Hasiec B., Cwinarowiczliwa E., Belli R., Abdel-Messih IA., Beygo J., Fragapane E. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. Journal of Preventive Medicine and Hygiene, 53: 136-142. 2012.

De Wit JJ., Cazaban C., Dijkman R., Ramon G., Gardin Y. Detection of different genotypes of infectious bronchitis virus and of infectious bursal disease virus in European broilers during an epidemiological study in 2013 and the consequences for the diagnostic approach. Avian Pathology, 24: 1-12. 2017.

Dhama K., Singh SD., Barathidasan R., Desingu PA., Chakraborty S., Tiwari R., Kumar, MA. Emergence of Avian Infectious Bronchitis Virus and its variants need better diagnosis, prevention and control strategies: a global perspective. Pakistan Journal of Biological Sciences, 17: 751-767. 2014.

Gan L., Tian Y., Zhao Y., Shan XQ., Zhou W., Xia BB., Chen J., Wang ML., Zhao J. Enhancing immunogenicity and protective efficacy of inactivated avian influenza
H9N2 vaccine with recombinant chicken IFN-α in chicken. Veterinary microbiology, 234: 77-82. 2019.

Habibi M., Karimi V., Langeroudi AG., Ghafouri SA., Hashemzadeh M., Farahani RK., Maghsoudloo H., Abdollahi H., Seifouri P. Combination of H120 and 1/96 avian infectious bronchitis virus vaccine strains protect chickens against challenge with IS/1494/06 (variant 2)-like infectious bronchitis virus. Acta virologica, 61: 150-160. 2017.

Han JW., Jiang XM., Zhang LD. Optimisation of extraction conditions for polysaccharides from the roots of Isatis tinctoria L. by response surface methodology and their in vitro free radicals scavenging activities and effects on IL-4 and IFN-γ mRNA expression in chicken lymphocytes. Carbohydrate Polymers, 86: 1320-1326. 2011.

Janardhana V., Ford ME., Bruce MP., Broadway MM., O’ Neil TE., Karpala AJ., Asif M., Browning GF., Tivendale KA., Noormohammadi AH., Lowenthal JW., Bean AG. IFN-gamma enhances immune responses to E. coli infection in the chicken. Journal of interferon and cytokine research, 27: 937 - 946. 2007.

Jain P., Kumar S., Arora B., Singh S., Chabbra S., Sen R. Comparison of Prostatic Tissue Processed by Microwave and Conventional Technique Using Morphometry. Iranian Journal of Pathology, 10: 1-8. 2015.

Jiang W., Jiang P., Li Y., Tang J., Wang X., Ma S. Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus
induce both humoral and cell-mediated immune responses in mice. Veterinary
Immunology and Immunopathology, 113: 169-180. 2006.

Kano R., Konnai S., Onuma M., Ohashi K. Cytokine profiles in chickens infected with
virulent and avirulent Marek’s disease viruses: interferon-gamma is a key factor in
the protection of Marek’s disease by vaccination. Microbiology and Immunology, 53:
224 - 232. 2009.

Katz D., Kohn A. Antibodies in blood and secretions of chickens immunized parenterally
and locally with killed Newcastle disease virus vaccine. Developments in biological
standardization, 33: 290-296. 1976.

Khan S., Roberts J., Wu SB. Reference gene selection for gene expression study in shell
gland and spleen of laying hens challenged with infectious bronchitis virus. Scientific
Reports, 7: 14271. 2017.

Liu X., Ma H., Xu Q., Sun N., Han Z., Sun C., Guo H., Shao Y., Kong X., Liu S.
Characterization of a recombinant coronavirus infectious bronchitis virus with
distinct S1 subunits of spike and nucleocapsid genes and a 3’ untranslated region.
Veterinary Microbiology, 162: 429-436. 2013.

Martinez-Lopez A., Garcia-Valtanen P., Ortega-Villaizan M., Chico V., Gomez-Casado
E., Coll JM., Estepa A. VHSV G glycoprotein major determinants implicated in
triggering the host type I IFN antiviral response as DNA vaccine molecular adjuvants.
Vaccine, 32: 6012-6019. 2014.
Mase M., Kawanishi N., Ootani Y., Murayama K., Karino A., Inoue T., Kawakami J. A novel genotype of avian infectious bronchitis virus isolated in Japan in 2009. The Journal of Veterinary Medical Science, 72: 1265-1268. 2010.

Meir R., Maharat O., Farnushi Y., Simanov L. Development of a real-time TaqMan RT-PCR assay for the detection of infectious bronchitis virus in chickens, and comparison of RT-PCR and virus isolation. Journal of Virological Methods, 163: 190-194. 2010.

Nyakudya E, Jeong JH., Lee NK., Jeong YS. Platycosides from the Roots of *Platycodon grandiflorum* and Their Health Benefits. Preventive Nutrition and Food Science, 19(2): 59-68. 2014.

Office International des Epizooties (O.I.E.), Manual of standards for diagnostic tests and vaccines, Avian Infectious Bronchitis, 6th edn, pp. 443–455. 2008.

Oliveira ER., Gonçalves AJ., Costa SM., Azevedo AS., Mantuano-Barradas M., Nogueira AC., Alves AM. Aspects of T Cell-Mediated Immunity Induced in Mice by a DNA Vaccine Based on the Dengue-NS1 Antigen after Challenge by the Intracerebral Route. PLoS One, 11(9): e0163240. 2016.

Okino CH., Mores MA., Trevisol IM., Coldebell A., Montassier HJ., Brentano L. Early immune responses and development of pathogenesis of avian infectious bronchitis viruses with different virulence profiles. PLoS One, 12(2): e0172275. 2017.

Reed LJ., Muench HA. A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology, 27: 493 - 497. 1938.
Smith J., Sadeyen JR., Cavanagh D., Kaiser P., Burt DW. The early immune response to infection of chickens with Infectious Bronchitis Virus (IBV) in susceptible and resistant birds. BMC Veterinary Research, 11: 256. 2015.

Sjölander A., Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Advanced drug delivery reviews, 34: 321-338. 1998.

Sun H., Chen L., Wang J., Wang K., Zhou J. Structure-function relationship of the saponins from the roots of Platycodon grandiflorum for hemolytic and adjuvant activity. International Immunopharmacology, 11(12): 2047-56. 2011.

Toro H., Pennington D., Gallardo RA., van Santen VL., van Ginkel FW., Zhang J., Joiner KS. Infectious bronchitis virus subpopulations in vaccinated chickens after challenge. Avian Diseases, 56: 501-508. 2012.

Wang YF., Sun YK., Tian ZC., Shi XM., Tong GZ., Liu SW., Zhi HD., Kong XG., Wang M. Protection of chickens against infectious bronchitis by a recombinant fowlpox virus co-expressing IBV-S1 and chicken IFNgamma. Vaccine, 27: 7046-7052. 2009.

Xie Y., Sun HX., Li D. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine, 27(5): 757-764. 2009.

Xie Y., Deng W., Sun H., Li D. Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses. International Immunopharmacology, 8(8): 1143-1150. 2008.
Yu J., Shi FS., Hu S. Improved immune responses to a bivalent vaccine of Newcastle disease and avian influenza in chickens by ginseng stem-leaf saponins. Veterinary immunology and immunopathology, 167: 147-155. 2015.

Zeshan B., Mushtaq MH., Wang X., Li W., Jiang P. Protective immune responses induced by in ovo immunization with recombinant adenoviruses expressing spike (S1) glycoprotein of infectious bronchitis virus fused/co-administered with granulocyte-macrophage colony stimulating factor. Veterinary Microbiology, 148: 8-17. 2011.

Zhang P., Wang J., Wang W., Liu X., Liu H., Li X., Wu X. Astragalus polysaccharides enhance the immune response to avian infectious bronchitis virus vaccination in chickens. Microbial Pathogenesis, 111: 81-85. 2017.

Zhou Y., Zhou M., Zhang D., Zhang H., Zhang L. Immune response of AA broilers to IBV H120 vaccine and sodium new houttuynfate. Research in Veterinary Science, 89: 373-377. 2010.

**Figure Legends**

Fig. 1. The influence of PD on the proliferation of chicken PBMCs, as measured by MTT assay. The culture medium served as the negative control. Error bars represent SE
(n=8). Means within a treatment group labeled with different letters (a, b, or c) are significantly different ($P < 0.05$).

Fig. 2. The concentration of IFN-γ in the sera of vaccinated chickens. Error bars represent SE (n=8). Means within a treatment group labeled with different letters (a, b, or c) are significantly different ($P < 0.05$).

Fig. 3. Histological lesions in the lungs and kidneys of chickens at day 5 post-challenge (200× magnification under a light microscope). A and C, Representative (A) lung and (C) kidney micrographs of control chickens. B and D, Representative (B) lung and (D) kidney micrographs of chickens treated with PD. Control chickens showed more severe nephritis compared to chickens treated with PD. The arrows indicate areas of pathological lesions.
Table 1. Dynamic variations in antibody titers in chickens (log2)

| Treatment group | Days post immunization (dpi) |          |          |          |
|-----------------|-----------------------------|----------|----------|----------|
|                 | 0              | 14       | 21       | 28       |
| PBS             | 0              | 0        | 0        | 0        |
| IBV H120        | 0.5 ± 0.2      | 3.2 ± 0.4 b | 4.1 ± 0.3 c | 4.3 ± 0.1 c |
| IBV H120 + 0.25 mg/mL PD | 0.5 ± 0.3 | 4.0 ± 0.4 a | 4.5 ± 0.6 c | 4.3 ± 0.6 c |
| IBV H120 + 0.5 mg/mL PD | 0.3 ± 0.1 | 3.7 ± 0.4 b | 5.9 ± 0.4 b | 5.9 ± 0.4 b |
| IBV H120 + 1 mg/mL PD | 0.4 ± 0.2 | 4.7 ± 0.7 a | 6.5 ± 0.7 a | 6.9 ± 0.3 a |
| IBV H120 + Al(OH)3 | 0.6 ± 0.4 | 3.1 ± 0.5 b | 5.7 ± 0.3 b | 5.7 ± 0.7 b |

PBS, phosphate buffered solution; IBV, infectious bronchitis virus.

Means within the same column appended by different letters (a, b, and c) are significantly different ($P < 0.05$). Values are expressed as means ± SE.
Table 2. Protective effects of platycodin D immunization against infectious bronchitis virus (IBV) strain M41 in 5-week-old SPF chickens.

| Treatment group       | Number of dead chickens<sup>a</sup> | Number of affected chickens<sup>b</sup> | Mortality (%) | Protection (%)<sup>c</sup> |
|-----------------------|--------------------------------------|----------------------------------------|---------------|-----------------------------|
| PBS                   | 13/30                                | 30/30                                  | 43.3          | 0                           |
| IBV H120              | 5/30                                 | 9/30                                   | 16.7          | 70.0                        |
| IBV H120 + 0.25 mg/mL PD | 5/30                                | 5/30                                   | 16.7          | 83.3                        |
| IBV H120 + 0.5 mg/mL PD | 0/30                                | 1/30                                   | 0             | 96.7                        |
| IBV H120 + 1 mg/mL PD  | 1/30                                 | 1/30                                   | 3.3           | 96.7                        |
| IBV H120 + Al(OH)3     | 2/30                                 | 5/30                                   | 6.6           | 83.3                        |

(a) The number of deaths was recorded each day post-challenge, and is presented as the total number of dead chickens in each group.

(b) IBV infection was detected in all chickens by RT-PCR, as indicated by the expression of IBV N protein in the lung and/or kidney tissues.

(c) Percent protection represents the number of unaffected chickens divided by the total number of chickens in each group.
Fig. 1
